NMT Medical Completes Enrollment for PFO/Stroke Trial
Posted on: Friday, 10 October 2008, 09:00 CDT
NMT Medical, a medical technology company, has completed patient enrollment in its pivotal patent foramen ovale/stroke clinical trial, Closure I.
NMT believes that it is the first company to complete enrollment of a prospective, multi-center, randomized, controlled study that examines the potential relationship between patent foramen ovale (PFO) and stroke and transient ischemic attacks (TIA). The company also believes it will be first to submit a pre-market approval application to the FDA for the PFO/stroke and TIA indication.
Closure I is designed to compare the effectiveness of the StarFlex septal repair implant technology against drug therapy in reducing the risk of recurrent stroke and TIA in patients with a PFO. Of the 900 stroke and TIA patients enrolled in the study, half received PFO closure in a catheter-based procedure with NMT's StareFlex implant and half will be treated with drugs alone.
More than 190 leading stroke neurologists and interventional cardiologists at approximately 95 centers in the US, Canada and the UK are participating in the Closure I study.
John Ahern, president and CEO of NMT Medical, said: "Completing patient enrollment in our Closure I clinical trial is an important milestone for NMT Medical and our investigator partners. We believe that data from Closure I will help the clinical community and stroke and TIA patients diagnosed with a PFO shunt make informed decisions as to the best course of therapy."
Source: Datamonitor
Related Articles
- Oncolytics Biotech Inc. Treats 200th Cancer Patient in Clinical Studies With REOLYSIN(R)
- Praxis Launches Patient Recruitment Program for Women's Health Medical Research Studies
- New Study Demonstrated That Extending Prophylaxis With Lovenox(R) (Enoxaparin Sodium Injection) to 5 Weeks Was More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely Ill Medical Patients With Reduced Mobility
- New Study Shows That Extending Prophylaxis With Clexane(R) / Lovenox(R) (Enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely Ill Medical Patients With Reduced Mobility
- Companion Technologies Adds Web Interface for Medical Patient Statements
- Diabetes Prevention Trial Enrolls First Patients; Study Seeks Additional Volunteers in California, Texas, Louisiana
- Antibiotic Utilization and Outcomes for Patients With Clinically Suspected Ventilator-Associated Pneumonia and Negative Quantitative BAL Culture Results*
- Quality-of-Life Determinants in Patients With Clinically Stable Bronchiectasis*
- Dalteparin Reduced Venous Thromboembolic Events Without Increased Bleeding in Acutely Ill Medical Patients/COMMENTARY
- U. Enlists Patients in Clinical Study Linked to Fatal Lung Disease
 |
 |
User Comments (0)
RSS Feeds